在患有2型糖尿病的患者中,添加费诺纤维酸与黄素添加到格利梅皮里德的效果:一项随机对照试验
Eman M Nada1, Nashwa M El-Gharbawy2, Haidy Abbas3
1Department of Clinical Pharmacy, Ministry of Health and Population, Damanhour, Egypt.
BMC pharmacology & toxicology
|June 6, 2025
概括
纤维酸和黄素可以改善2型糖尿病患者的脂质样本和炎症标志物. 费诺纤维酸在减少腰围和fetuin-A以及增加sirtuin 1方面表现出额外的益处.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病是心血管疾病的重要危险因素.
- 超脂血症在糖尿病患者中很常见.
- 纤维酸和黄素已经显示出在治疗糖尿病高脂血症方面的潜力.
研究的目的:
- 为了评估添加 fenofibrate 或黄素 加入 glimepiride 治疗的效果.
- 为了评估体重,血糖状况,脂质,hs-CRP,fetuin-A和sirtuin的变化 1.
- 为了在2型糖尿病患者中比较费诺纤维酸与黄素的疗效.
主要方法:
- 一个为期3个月的双盲随机对照试验,涉及60名2型糖尿病患者.
- 患者接受了glimepiride加上安慰剂,黄素 (1100毫克/天) 或纤维酸 (160毫克/天).
- 测量包括人体测量和生物化学标记 (葡萄糖,HbA1c,脂质,hs-CRP,fetuin-A,sirtuin 1).
主要成果:
- 两组之间没有观察到体重,BMI,禁食葡萄糖,2h-PPG或HbA1c的显著差异.
- 纤维酸和黄素都显著降低了脂质样本 (TC,TG,LDL-C,非HDL-C,VLDL-C,CRI,AI) 和hs-CRP,同时与安慰剂相比增加了Sirtuin 1.
- 与安慰剂相比,纤维酸显著增加了HDL-C.
- 费诺纤维酸在减少腰围,fetuin-A和增加sirtuin 1方面表现出比黄素更好的效果.
结论:
- 纤维酸和黄素都能有效地改善2型糖尿病患者的脂质样本和炎症标志物.
- 费诺纤维酸可能在减少腰围,降低fetuin-A水平和增强sirtuin 1活性方面提供额外的优势.
- 这些发现表明,纤维酸和黄素在控制与2型糖尿病相关的心血管风险因素方面具有潜在的治疗作用.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Diabetes: Management and Pharmacotherapy
412
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
412
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
278
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
278
Oral Hypoglycemic Agents: Sulfonylureas
353
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
353


